Literature DB >> 28362407

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis.

Kaitlyn Schaaf1, Samuel R Smith1, Virginia Hayley1, Olaf Kutsch1, Jim Sun2.   

Abstract

The early drug development process for anti-tuberculosis drugs is hindered by the inefficient translation of compounds with in vitro activity to effectiveness in the clinical setting. This is likely due to a lack of consideration for the physiologically relevant cellular penetration barriers that exist in the infected host. We recently established an alternative infection model that generates large macrophage aggregate structures containing densely packed M. tuberculosis (Mtb) at its core, which was suitable for drug susceptibility testing. This infection model is inexpensive, rapid, and most importantly BSL-2 compatible. Here, we describe the experimental procedures to generate Mtb/macrophage aggregate structures that would produce macrophage-passaged Mtb for drug susceptibility testing. In particular, we demonstrate how this infection system could be directly adapted to the 96-well plate format showing throughput capability for the screening of compound libraries against Mtb. Overall, this assay is a valuable addition to the currently available Mtb drug discovery toolbox due to its simplicity, cost effectiveness, and scalability.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28362407      PMCID: PMC5409311          DOI: 10.3791/55453

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  21 in total

1.  Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.

Authors:  Ruben C Hartkoorn; Becky Chandler; Andrew Owen; Stephen A Ward; S Bertel Squire; David J Back; Saye H Khoo
Journal:  Tuberculosis (Edinb)       Date:  2007-01-26       Impact factor: 3.131

Review 2.  The future for early-stage tuberculosis drug discovery.

Authors:  Edison S Zuniga; Julie Early; Tanya Parish
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

Review 3.  Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.

Authors:  P R Donald
Journal:  Tuberculosis (Edinb)       Date:  2010-08-14       Impact factor: 3.131

Review 4.  Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

Authors:  Jakko van Ingen; Rob E Aarnoutse; Peter R Donald; Andreas H Diacon; Rodney Dawson; Georgette Plemper van Balen; Stephen H Gillespie; Martin J Boeree
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 5.  Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them.

Authors:  Dimitrios Evangelopoulos; Joana Diniz da Fonseca; Simon J Waddell
Journal:  Int J Infect Dis       Date:  2015-03       Impact factor: 3.623

6.  Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.

Authors:  Jansy Sarathy; Véronique Dartois; Thomas Dick; Martin Gengenbacher
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

7.  The role of the granuloma in expansion and dissemination of early tuberculous infection.

Authors:  J Muse Davis; Lalita Ramakrishnan
Journal:  Cell       Date:  2009-01-09       Impact factor: 41.582

8.  Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages.

Authors:  Flavia Sorrentino; Ruben Gonzalez del Rio; Xingji Zheng; Jesus Presa Matilla; Pedro Torres Gomez; Maria Martinez Hoyos; Maria Esther Perez Herran; Alfonso Mendoza Losana; Yossef Av-Gay
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

9.  Assessment of immunity to mycobacterial infection with luciferase reporter constructs.

Authors:  V A Snewin; M P Gares; P O Gaora; Z Hasan; I N Brown; D B Young
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

10.  Looking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosis.

Authors:  Sean Ekins; Richard Pottorf; Robert C Reynolds; Antony J Williams; Alex M Clark; Joel S Freundlich
Journal:  J Chem Inf Model       Date:  2014-04-03       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.